{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:13:37Z","timestamp":1787022817260,"version":"build-2736575974"},"reference-count":0,"publisher":"Bioscientifica","issue":"3","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"\n We developed a clinical score (CS) at Vanderbilt Ingram Cancer Center (VICC) that we hoped would predict outcomes for patients with progressive well-differentiated neuroendocrine tumors (NETs) receiving therapy with Lutetium-177 (\n 177<\/jats:sup>\n Lu)-DOTATATE. Patients under consideration for\n 177<\/jats:sup>\n Lu-DOTATATE between March 1, 2016 and March 17, 2020 at VICC were assigned a CS prospectively. The CS included 5 categories: available treatments for tumor type outside of\n 177<\/jats:sup>\n Lu-DOTATATE, prior systemic treatments, patient symptoms, tumor burden in critical organs and presence of peritoneal carcinomatosis. The primary outcome of the analysis was progression-free survival (PFS). To evaluate the effect of the CS on PFS, a multivariable Cox regression analysis was performed adjusting for tumor grade, primary tumor location, and the interaction between\n 177<\/jats:sup>\n Lu-DOTATATE doses received (zero, 1\u20132, 3\u20134) and CS. A total of 91 patients and 31 patients received 3\u20134 doses and zero doses of\n 177<\/jats:sup>\n Lu-DOTATATE, respectively. On multivariable analysis, in patients treated with 3\u20134 doses of\n 177<\/jats:sup>\n Lu-DOTATATE, for each 1-point increase in CS, the estimated hazard ratio (HR) for PFS was 2.0 (95% CI 1.61\u20132.48). On multivariable analysis, in patients who received zero doses of\n 177<\/jats:sup>\n Lu-DOTATATE, for each 1-point increase in CS, the estimated HR for PFS was 1.22 (95% CI 0.91\u20131.65). Among patients treated with 3\u20134 doses of 177Lu-DOTATATE, those with lower CS experienced improved PFS with the treatment compared to patients with higher CS. This PFS difference, based upon CS, was not observed in patients who did not receive\n 177<\/jats:sup>\n Lu-DOTATATE, suggesting the predictive utility of the score.\n <\/jats:p>","DOI":"10.1530\/erc-20-0482","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T11:25:50Z","timestamp":1613733950000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":8,"title":["A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy"],"prefix":"10.1530","volume":"28","author":[{"given":"Satya","family":"Das","sequence":"first","affiliation":[{"name":"1Vanderbilt University Medical Center, Division of Hematology and Oncology, Department of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[{"name":"2Vanderbilt University of Medical Center, Department of Biostatistics, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Schad","sequence":"additional","affiliation":[{"name":"3Rush Medical Center, Department of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Jain","sequence":"additional","affiliation":[{"name":"4Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Jessop","sequence":"additional","affiliation":[{"name":"5Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirayu","family":"Shah","sequence":"additional","affiliation":[{"name":"5Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eisner","sequence":"additional","affiliation":[{"name":"1Vanderbilt University Medical Center, Division of Hematology and Oncology, Department of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Cardin","sequence":"additional","affiliation":[{"name":"1Vanderbilt University Medical Center, Division of Hematology and Oncology, Department of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Ciombor","sequence":"additional","affiliation":[{"name":"1Vanderbilt University Medical Center, Division of Hematology and Oncology, Department of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Goff","sequence":"additional","affiliation":[{"name":"1Vanderbilt University Medical Center, Division of Hematology and Oncology, Department of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marques","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"5Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Delbeke","sequence":"additional","affiliation":[{"name":"5Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sandler","sequence":"additional","affiliation":[{"name":"5Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[{"name":"1Vanderbilt University Medical Center, Division of Hematology and Oncology, Department of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/28\/3\/ERC-20-0482.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/28\/3\/ERC-20-0482.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:55:54Z","timestamp":1784555754000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/28\/3\/203-212\/25530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":0,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/erc-20-0482","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}